Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Toxicol In Vitro ; 47: 147-155, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29154941

ABSTRACT

Bisphenol A (BPA) is a high production volume compound. It is mainly used as a monomer to make polymers for various applications including food-contact materials. The primary route of exposure to BPA in the general population is through oral intake (EFSA 2015) however, other potential sources of exposure have also been identified, such as dermal contact. In the present study, the percutaneous absorption through human skin has been investigated in an in vitro study according to OECD TG 428 (Skin Absorption: In Vitro Method). In order to investigate potential dermal BPA metabolism during absorption, radiolabelled BPA was applied to fresh, metabolically competent, human skin samples (ring labelled 14C BPA concentrations tested were 2.4, 12, 60 and 300mg/L). Measured as total radioactivity the mean absorbed dose (receptor compartment) ranged from 1.7-3.6% of the applied doses and the dermal delivery (epidermis+dermis+receptor compartment), sometimes also named bioavailable dose was 16-20% of the applied doses, with the majority of the radioactivity associated with epidermis compared to dermis and receptor fluid. No metabolism was observed in any of the epidermis samples; however some metabolism was observed in dermis and receptor fluid samples with formation of BPA-glucuronide and BPA-sulfate, and some polar metabolites.


Subject(s)
Benzhydryl Compounds/metabolism , Environmental Pollutants/metabolism , Phenols/metabolism , Skin Absorption , Skin/metabolism , Administration, Cutaneous , Adult , Benzhydryl Compounds/administration & dosage , Biotransformation , Carbon Radioisotopes , Dermis/metabolism , Environmental Pollutants/administration & dosage , Epidermis/metabolism , Female , Glucuronides/metabolism , Humans , Kinetics , Male , Middle Aged , Organ Specificity , Phenols/administration & dosage , Reproducibility of Results , Sulfates/metabolism , Tissue Culture Techniques , Tissue Distribution
2.
Article in English | MEDLINE | ID: mdl-26465088

ABSTRACT

The aim of the presented investigation was to document challenges encountered during implementation and qualification of a method for bisphenol A (BPA) analysis and to develop and discuss precautions taken to avoid and to monitor contamination with BPA during sample handling and analysis. Previously developed and published HPLC-MS/MS methods for the determination of unconjugated BPA (Markham et al. Journal of Analytical Toxicology, 34 (2010) 293-303) [17] and total BPA (Markham et al. Journal of Analytical Toxicology, 38 (2014) 194-203) [20] in human urine were combined and transferred into another laboratory. The initial method for unconjugated BPA was developed and evaluated in two independent laboratories simultaneously. The second method for total BPA was developed and evaluated in one of these laboratories to conserve resources. Accurate analysis of BPA at sub-ppb levels is a challenging task as BPA is a widely used material and is ubiquitous in the environment at trace concentrations. Propensity for contamination of biological samples with BPA is reported in the literature during sample collection, storage, and/or analysis. Contamination by trace levels of BPA is so pervasive that even with extraordinary care, it is difficult to completely exclude the introduction of BPA into biological samples and, consequently, contamination might have an impact on BPA biomonitoring data. The applied UPLC-MS/MS method was calibrated from 0.05 to 25ng/ml. The limit of quantification was 0.1ng/ml for unconjugated BPA and 0.2ng/ml for total BPA, respectively, in human urine. Finally, the method was applied to urine samples derived from 20 volunteers. Overall, BPA can be analyzed in human urine with acceptable recovery and repeatability if sufficient measures are taken to avoid contamination throughout the procedure from sample collection until UPLC-MS/MS analysis.


Subject(s)
Benzhydryl Compounds/chemistry , Benzhydryl Compounds/urine , Chromatography, High Pressure Liquid/methods , Phenols/chemistry , Phenols/urine , Solid Phase Extraction/methods , Tandem Mass Spectrometry/methods , Benzhydryl Compounds/isolation & purification , Humans , Linear Models , Phenols/isolation & purification , Reproducibility of Results , Sensitivity and Specificity
3.
Toxicology ; 333: 168-178, 2015 Jul 03.
Article in English | MEDLINE | ID: mdl-25929835

ABSTRACT

Orally administered bisphenol A (BPA) undergoes efficient first-pass metabolism to produce the inactive conjugates BPA-glucuronide (BPA-G) and BPA-sulfate (BPA-S). This study was conducted to evaluate the pharmacokinetics of BPA, BPA-G and BPA-S in neonatal mice following the administration of a single oral or subcutaneous (SC) dose. This study consisted of 3 phases: (1) mass-balance phase in which effective dose delivery procedures for oral or SC administration of (3)H-BPA to postnatal day three (PND3) mice were developed; (2) pharmacokinetic phase during which systemic exposure to total (3)H-BPA-derived radioactivity in female PND3 mice was established; and (3) metabolite profiling phase in which 50 female PND3 pups received either a single oral or SC dose of (3)H-BPA. Blood was collected from 5 pups/route/time-point at various times post-dosing, the blood plasma samples were pooled by group, and time-point and samples were profiled by HPLC with fraction collection. Fractions were analyzed for total radioactivity and data used to reconstruct radiochromatograms and to integrate individual peaks. The identity of the BPA, BPA-G, and BPA-S peaks was confirmed using authentic standards and LC-MS/MS analysis. The result of this study revealed that female PND3 mice have the capacity to metabolize BPA to BPA-G, BPA-S and other metabolites after both routes of administration. Systemic exposure to free BPA is route-dependent as the plasma concentrations were lower following oral administration compared to SC injection.


Subject(s)
Benzhydryl Compounds/administration & dosage , Benzhydryl Compounds/pharmacokinetics , Phenols/administration & dosage , Phenols/pharmacokinetics , Administration, Oral , Animals , Animals, Newborn , Benzhydryl Compounds/blood , Biotransformation , Chromatography, High Pressure Liquid , Female , Glucuronides/pharmacokinetics , Injections, Subcutaneous , Metabolomics/methods , Mice , Phenols/blood , Sulfates/pharmacokinetics , Tandem Mass Spectrometry
4.
J Anal Toxicol ; 38(4): 194-203, 2014 May.
Article in English | MEDLINE | ID: mdl-24567285

ABSTRACT

This publication describes a method for the determination of total bisphenol A (BPA and conjugated BPA) following enzyme hydrolysis and is intended as a companion to our previously developed analytical method for the determination of free BPA (the aglycone) in human blood and urine using high-performance liquid chromatography-tandem mass spectrometry ( 1). That free BPA method provided a means to account for and/or eliminate background contamination and demonstrated accuracy and reproducibility in both matrices fortified with BPA or a surrogate analyte ((13)C BPA) at a low method quantitation limit (MQL) of 0.1-0.2 ng/mL. In contrast to the free BPA method results and based on stringent accuracy, precision and confirmation criteria set for the MQLs of the method developed for total BPA, the MQL achieved in blood was 1.020-2.550 and 0.510-1.020 ng/mL in urine. These data showed higher MQLs than the desired MQLs of 0.5 ng/mL (blood) and 0.2 ng/mL (urine) with increased variability between analyses which demonstrates the importance of generating method validation data with each analysis. In contrast, the MQL achieved for (13)C BPA-G (monoglucuronide as a surrogate analyte in blood was 0.2-0.5 and 0.2 ng/mL in urine illustrating that the method is capable of meeting lower MQL requirements if the contribution from exogenous BPA can be well controlled. This method for the determination total BPA in human blood and urine is intended to be used in conjunction with the free BPA method ( 1) to obtain accurate and complete BPA biomonitoring data to support human exposure assessments.


Subject(s)
Benzhydryl Compounds , Chromatography, High Pressure Liquid/methods , Environmental Monitoring/methods , Environmental Pollutants , Phenols , Spectrometry, Mass, Electrospray Ionization/methods , Tandem Mass Spectrometry/methods , Benzhydryl Compounds/blood , Benzhydryl Compounds/urine , Calibration , Chromatography, High Pressure Liquid/instrumentation , Environmental Monitoring/instrumentation , Environmental Pollutants/blood , Environmental Pollutants/urine , Humans , Limit of Detection , Phenols/blood , Phenols/urine , Reference Standards , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization/instrumentation , Tandem Mass Spectrometry/instrumentation
5.
Heart Rhythm ; 8(11): 1705-11, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21726519

ABSTRACT

BACKGROUND: Catheter ablation of atrial fibrillation (AF) is complicated by cerebral emboli resulting in acute ischemia. Recently, cerebral ischemic microlesions have been identified with diffusion-weighted magnet resonance imaging (MRI). OBJECTIVE: The clinical course and longer-term characteristics of these lesions are not known and were investigated in this study. METHODS: Of 86 patients, 33 (38%) had new asymptomatic cerebral lesions documented on MRI after catheter ablation for AF; 14 of these 33 (42%) underwent repeat MRI at different time intervals (2 weeks to 1 year) during follow-up, and clinical symptoms as well as size and number of residual lesions were documented. RESULTS: In postablation cerebral MRI, 50 new lesions were identified (3.6 lesions/patient) in 14 patients. No patient presented any neurological symptoms. Distribution of the lesions was predominantly in the left hemisphere (60%) and the cerebellum (26%); 52% of the lesions were small (≤3 mm maximum diameter), 42% were medium (4 to 10 mm) and 3 lesions (6%) had a maximum diameter >10 mm. Follow-up MRI after a median of 3 months revealed 3 residual lesions in 3 of 14 patients corresponding to the large acute postablation lesions (>10 mm). The remaining 47 of 50 (94%) of the small or medium-sized lesions were not detectable at follow-up evaluation. CONCLUSIONS: Most asymptomatic cerebral lesions observed acutely after AF ablation procedures were ≤10 mm in diameter. 94% of all lesions healed without scarring at follow-up >2 weeks after ablation. The larger acute lesions produced chronic glial scars. Neither chronic nor acute lesions were associated with neurological symptoms.


Subject(s)
Atrial Fibrillation/surgery , Catheter Ablation/adverse effects , Intracranial Embolism/diagnosis , Magnetic Resonance Imaging/methods , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Intracranial Embolism/etiology , Male , Middle Aged , Prognosis , Time Factors
6.
Toxicol Sci ; 115(1): 167-82, 2010 May.
Article in English | MEDLINE | ID: mdl-20164145

ABSTRACT

This study was conducted to determine the potential of bisphenol A (BPA) to induce functional and/or morphological effects to the nervous system of F(1) offspring from dietary exposure during gestation and lactation according to the Organization for Economic Cooperation and Development and U.S. Environmental Protection Agency guidelines for the study of developmental neurotoxicity. BPA was offered to female Sprague-Dawley Crl:CD (SD) rats (24 per dose group) and their litters at dietary concentrations of 0 (control), 0.15, 1.5, 75, 750, and 2250 ppm daily from gestation day 0 through lactation day 21. F(1) offspring were evaluated using the following tests: detailed clinical observations (postnatal days [PNDs] 4, 11, 21, 35, 45, and 60), auditory startle (PNDs 20 and 60), motor activity (PNDs 13, 17, 21, and 61), learning and memory using the Biel water maze (PNDs 22 and 62), and brain and nervous system neuropathology and brain morphometry (PNDs 21 and 72). For F(1) offspring, there were no treatment-related neurobehavioral effects, nor was there evidence of neuropathology or effects on brain morphometry. Based on maternal and offspring body weight reductions, the no-observed-adverse-effect level (NOAEL) for systemic toxicity was 75 ppm (5.85 and 13.1 mg/kg/day during gestation and lactation, respectively), with no treatment-related effects at lower doses or nonmonotonic dose responses observed for any parameter. There was no evidence that BPA is a developmental neurotoxicant in rats, and the NOAEL for developmental neurotoxicity was 2250 ppm, the highest dose tested (164 and 410 mg/kg/day during gestation and lactation, respectively).


Subject(s)
Air Pollutants, Occupational/toxicity , Nervous System Diseases/chemically induced , Nervous System/drug effects , Phenols/toxicity , Abnormalities, Drug-Induced , Animals , Animals, Newborn , Benzhydryl Compounds , Brain/drug effects , Brain/embryology , Brain/growth & development , Female , Lactation/drug effects , Longevity/drug effects , Male , Maternal Exposure , Maze Learning/drug effects , Motor Activity/drug effects , Nervous System/embryology , Nervous System/growth & development , Nervous System Diseases/embryology , Nervous System Diseases/pathology , Pregnancy , Rats , Rats, Sprague-Dawley
8.
Toxicol Sci ; 104(2): 362-84, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18445619

ABSTRACT

Dietary bisphenol A (BPA) was evaluated in a mouse two-generation study at 0, 0.018, 0.18, 1.8, 30, 300, or 3500 ppm (0, 0.003, 0.03, 0.3, 5, 50, or 600 mg BPA/kg/day, 28 per sex per group). A concurrent positive control group of dietary 17beta-estradiol (0.5 ppm; 28 per sex) confirmed the sensitivity of CD-1 mice to an endogenous estrogen. There were no BPA-related effects on adult mating, fertility or gestational indices, ovarian primordial follicle counts, estrous cyclicity, precoital interval, offspring sex ratios or postnatal survival, sperm parameters or reproductive organ weights or histopathology (including the testes and prostate). Adult systemic effects: at 300 ppm, only centrilobular hepatocyte hypertrophy; at 3500 ppm, reduced body weight, increased kidney and liver weights, centrilobular hepatocyte hypertrophy, and renal nephropathy in males. At 3500 ppm, BPA also reduced F1/F2 weanling body weight, reduced weanling spleen and testes weights (with seminiferous tubule hypoplasia), slightly delayed preputial separation (PPS), and apparently increased the incidence of treatment-related, undescended testes only in weanlings, which did not result in adverse effects on adult reproductive structures or functions; this last finding is considered a developmental delay in the normal process of testes descent. It is likely that these transient effects were secondary to (and caused by) systemic toxicity. Gestational length was increased by 0.3 days in F1/F2 generations; the toxicological significance, if any, of this marginal difference is unknown. At lower doses (0.018-30 ppm), there were no treatment-related effects and no evidence of nonmonotonic dose-response curves for any parameter. The systemic no observable effect level (NOEL) was 30 ppm BPA (approximately 5 mg/kg/day); the reproductive/developmental NOEL was 300 ppm (approximately 50 mg/kg/day). Therefore, BPA is not considered a selective reproductive or developmental toxicant in mice.


Subject(s)
Environmental Pollutants/toxicity , Phenols/toxicity , Prenatal Exposure Delayed Effects/chemically induced , Reproduction/drug effects , Animals , Benzhydryl Compounds , Body Weight/drug effects , Cell Enlargement , Dose-Response Relationship, Drug , Female , Hepatocytes/drug effects , Hepatocytes/pathology , Kidney/drug effects , Kidney/pathology , Kidney Diseases/chemically induced , Kidney Diseases/pathology , Liver/drug effects , Liver/pathology , Male , Mice , Organ Size/drug effects , Pregnancy , Prenatal Exposure Delayed Effects/pathology , Prenatal Exposure Delayed Effects/physiopathology , Rabbits , Reproduction/physiology , Sexual Maturation/drug effects , Testis/drug effects , Testis/pathology , Time Factors , Toxicity Tests
9.
Methods Mol Med ; 142: 53-61, 2008.
Article in English | MEDLINE | ID: mdl-18437305

ABSTRACT

Aminoacyl-tRNA synthetases (aa-RS) attracted interest as potential targets for new antibacterial compounds. Most organisms express 20 aa-RSs: one for each amino acid. Aa-RSs are essential proteins in all living organisms. When one aa-RS is inhibited, the corresponding tRNA is not charged and is therefore unavailable for translation. This leads to protein synthesis inhibition, which in turn causes cell growth arrest. Consequently, each compound that inhibits any of the aa-RS could be a potential antibacterial agent. Only one aa-RS inhibitor, the Ile-RS inhibitor mupirocin, is currently marketed as an antibacterial agent. We focused on phenylalanyl (Phe)-tRNA synthetase (Phe-RS), but the described methods are not restricted to Phe-RS and might be adapted to other aa-RS.


Subject(s)
Amino Acyl-tRNA Synthetases/antagonists & inhibitors , Bacteria/drug effects , Enzyme Inhibitors/analysis , Amino Acids/blood , Animals , Anti-Bacterial Agents/analysis , Anti-Bacterial Agents/pharmacology , Bacteria/enzymology , Bacteria/pathogenicity , Cell-Free System , Enzyme Inhibitors/pharmacology , Female , Humans , Mice , Microbial Sensitivity Tests , Phenylalanine-tRNA Ligase/antagonists & inhibitors , Sepsis/drug therapy , Sepsis/microbiology
10.
Nat Med ; 11(10): 1082-7, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16200071

ABSTRACT

Here we show that a new class of antibiotics-acyldepsipeptides-has antibacterial activity against Gram-positive bacteria in vitro and in several rodent models of bacterial infection. The acyldepsipeptides are active against isolates that are resistant to antibiotics in clinical application, implying a new target, which we identify as ClpP, the core unit of a major bacterial protease complex. ClpP is usually tightly regulated and strictly requires a member of the family of Clp-ATPases and often further accessory proteins for proteolytic activation. Binding of acyldepsipeptides to ClpP eliminates these safeguards. The acyldepsipeptide-activated ClpP core is capable of proteolytic degradation in the absence of the regulatory Clp-ATPases. Such uncontrolled proteolysis leads to inhibition of bacterial cell division and eventually cell death.


Subject(s)
Anti-Bacterial Agents/classification , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacteria/metabolism , Depsipeptides/pharmacology , Endopeptidase Clp/metabolism , Escherichia coli Proteins/metabolism , Animals , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/toxicity , Bacillus subtilis/drug effects , Bacteria/enzymology , Depsipeptides/metabolism , Depsipeptides/pharmacokinetics , Depsipeptides/toxicity , Drug Resistance, Multiple, Bacterial , Escherichia coli/drug effects , Female , Mice , Molecular Structure , Mutation , Pneumococcal Infections/drug therapy , Pneumococcal Infections/microbiology , Protein Binding , Protein Processing, Post-Translational , Rats , Rats, Wistar , Sepsis/drug therapy , Sepsis/microbiology
11.
Int J Cardiovasc Imaging ; 21(5): 549-54, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16175445

ABSTRACT

In patients with a low or intermediate probability of a coronary artery disease, ultrafast computer tomography (CT) of the coronary arteries and bypass grafts offer a novel approach for the evaluation of the coronary anatomy. The presented case impressively demonstrated the capability of ultrafast CT to show precisely the extent and localisation of a bypass artery stenosis in a patient with mild chest discomfort but negative stress testing. However, widespread screening of coronary artery disease with non-invasive imaging modalities can not be recommended until validated in larger studies that a complete visualization of all coronary arteries and bypass grafts can be achieved.


Subject(s)
Coronary Angiography/methods , Coronary Artery Bypass , Graft Occlusion, Vascular/diagnosis , Tomography, X-Ray Computed , Aged , Angioplasty, Balloon , Coronary Stenosis/diagnosis , Coronary Stenosis/therapy , Echocardiography, Stress , Exercise Test , Graft Occlusion, Vascular/therapy , Humans , Imaging, Three-Dimensional , Male , Stents
12.
Antimicrob Agents Chemother ; 48(2): 525-32, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14742205

ABSTRACT

Phenylalanyl (Phe)-tRNA synthetase (Phe-RS) is an essential enzyme which catalyzes the transfer of phenylalanine to the Phe-specific transfer RNA (tRNA(Phe)), a key step in protein biosynthesis. Phenyl-thiazolylurea-sulfonamides were identified as a novel class of potent inhibitors of bacterial Phe-RS by high-throughput screening and chemical variation of the screening hit. The compounds inhibit Phe-RS of Escherichia coli, Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus, with 50% inhibitory concentrations in the nanomolar range. Enzyme kinetic measurements demonstrated that the compounds bind competitively with respect to the natural substrate Phe. All derivatives are highly selective for the bacterial Phe-RS versus the corresponding mammalian cytoplasmic and human mitochondrial enzymes. Phenyl-thiazolylurea-sulfonamides displayed good in vitro activity against Staphylococcus, Streptococcus, Haemophilus, and Moraxella strains, reaching MICs below 1 micro g/ml. The antibacterial activity was partly antagonized by increasing concentrations of Phe in the culture broth in accordance with the competitive binding mode. Further evidence that inhibition of tRNA(Phe) charging is the antibacterial principle of this compound class was obtained by proteome analysis of Bacillus subtilis. Here, the phenyl-thiazolylurea-sulfonamides induced a protein pattern indicative of the stringent response. In addition, an E. coli strain carrying a relA mutation and defective in stringent response was more susceptible than its isogenic relA(+) parent strain. In vivo efficacy was investigated in a murine S. aureus sepsis model and a S. pneumoniae sepsis model in rats. Treatment with the phenyl-thiazolylurea-sulfonamides reduced the bacterial titer in various organs by up to 3 log units, supporting the potential value of Phe-RS as a target in antibacterial therapy.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacteria/enzymology , Enzyme Inhibitors/pharmacology , Animals , Bacillus subtilis/drug effects , Bacillus subtilis/genetics , CHO Cells , Colony Count, Microbial , Cricetinae , Drug Design , Escherichia coli/drug effects , Escherichia coli/enzymology , Female , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Mice , Microbial Sensitivity Tests , Pneumococcal Infections/drug therapy , Pneumococcal Infections/microbiology , Proteome/genetics , Rats , Rats, Wistar , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Substrate Specificity
13.
Cardiovasc Pathol ; 12(2): 115-7, 2003.
Article in English | MEDLINE | ID: mdl-12684171

ABSTRACT

Aortic coarctation was diagnosed in a 27-year-old man with Klippel-Feil syndrome, an inborn skeletal defect of the vertebral column associated with anomalies of various organs. The presented findings are discussed in the context to the theory of vascular artery supply disruption sequence during embryogenisis as a potential explanation for the pathogenesis of morphological defects of Klippel-Feil and associated syndromes.


Subject(s)
Aortic Coarctation/pathology , Klippel-Feil Syndrome/pathology , Adult , Aorta/pathology , Aortic Coarctation/etiology , Humans , Klippel-Feil Syndrome/complications , Magnetic Resonance Imaging , Male , Radiography, Thoracic
14.
Microbiology (Reading) ; 147(Pt 7): 1783-1791, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11429456

ABSTRACT

Peptide deformylation is an essential process in eubacteria. The peptide deformylase Def has been suggested to be an attractive target for antibacterial drug discovery. Some eubacteria including medically important pathogens possess two def-like genes. Until now, the functionality of both genes has been tested only in Staphylococcus aureus with the result that one gene copy was functional. Here, expression of two functional def-like gene products in Bacillus subtilis is demonstrated. Besides the def gene, which is chromosomally located close to the formyltransferase gene fmt and which was overexpressed and biochemically tested previously, B. subtilis possesses a second def-like gene, called ykrB. The encoded protein is 32% identical to the def gene product. It was shown that either def or ykrB had to be present for growth of B. subtilis in rich medium (each was individually dispensable). Studies with a def/ykrB double deletion strain with xylose-inducible ykrB copy demonstrated that, besides def, the gene ykrB is a second cellular target of deformylase inhibitors such as the antibiotic actinonin. The gene products exhibited similar enzymic properties, exemplified by similar inhibition efficacy of actinonin in biochemical assays. Antibiotic susceptibility tests with different deletion strains and Northern analyses indicated that YkrB is probably the predominant deformylase in B. subtilis. It was shown that duplication of the deformylase function does not lead to an increased actinonin-resistance frequency in comparison to B. subtilis mutants carrying only one deformylase gene.


Subject(s)
Amidohydrolases , Aminopeptidases/genetics , Aminopeptidases/metabolism , Bacillus subtilis/enzymology , Bacterial Proteins/metabolism , Amino Acid Sequence , Aminopeptidases/chemistry , Anti-Bacterial Agents/pharmacology , Bacillus subtilis/drug effects , Bacillus subtilis/genetics , Bacillus subtilis/growth & development , Bacterial Proteins/genetics , Catalytic Domain/genetics , Drug Resistance, Microbial , Gene Deletion , Hydroxamic Acids/pharmacology , Microbial Sensitivity Tests , Molecular Sequence Data , Polymerase Chain Reaction , Sequence Alignment
SELECTION OF CITATIONS
SEARCH DETAIL
...